Form 4: Immunovant CMO Sells Shares for Tax Obligations

Immunovant's Chief Medical Officer, Michael Geffner, sold 2,595 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Michael Geffner, Chief Medical Officer of Immunovant, Inc. (IMVT), sold 2,595 shares of common stock on October 22, 2025.
• The shares were sold at a weighted average price of $19.03, with transactions ranging from $19.03 to $19.20 per share.
• The sale was non-discretionary and mandated by Immunovant's policy to cover tax withholding obligations arising from the vesting of 6,250 Restricted Stock Units (RSUs).
• These RSUs vested on October 17, 2025, and were part of a larger grant of 100,000 RSUs awarded on January 17, 2023.
• Following this transaction, Michael Geffner beneficially owns 217,958 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The transaction is a neutral, non-discretionary 'sell to cover' event for tax purposes, not indicative of insider sentiment regarding the company's prospects.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This transaction is a routine 'sell to cover' event, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive dynamics within the biotechnology or pharmaceutical sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is non-discretionary and for tax purposes, not signaling a change in insider confidence. The number of shares sold is a small fraction of the total outstanding shares.
• Employees: No direct impact mentioned.
• Management: The Chief Medical Officer's beneficial ownership remains substantial, indicating continued alignment with shareholder interests.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Keywords

Immunovant, IMVT, Michael Geffner, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Chief Medical Officer